1 Belyaev A S, Roy P. Development of baculovirus triple and quadruple expression vectors: Co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells[J]. Nucleic Acids Research, 1993, 21(5): 1219~1223. 2 Cox M M. Recombinant protein vaccines produced in insect cells[J]. Vaccine, 2012, 30(10): 1759~1766. 3 de Diego A C P, Athmaram T N, Stewart M, et al. Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep[J]. PLoS One, 2011, 6(10): e26666. 4 de Smit A J, Bouma A, De Kluijver E P, et al. Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination[J]. Veterinary Microbiology, 2001, 78(4): 307~317. 5 Fan H, Ju C, Tong T, et al. Immunogenicity of empty capsids of porcine circovius type 2 produced in insect cells[J]. Veterinary Research Communications, 2007, 31(4): 487~496. 6 Hawtin R E, Zarkowska T, Arnold K, et al. Liquefaction of Autographa californica nucleopolyhedrovirus-infected insects is dependent on the integrity of virus-encoded chitinase and cathepsin genes[J]. Virology, 1997, 238(2): 243~253. 7 Hervas-Stubbs S, Rueda P, Lopez L, et al. Insect baculoviruses strongly potentiate adaptive immune responses by inducing typeⅠ IFN[J]. Journal of Immunology, 2007, 178(4): 2361~2369. 8 Jarvis D L. Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production[J]. Virology, 2003, 310(1): 1~7. 9 Latham T, Galarza J M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins[J]. Journal of Virology, 2001, 75(13): 6154~6165. 10 Lee D H, Kwon J S, Lee H J, et al. Inactivated H9N2 avian influenza virus vaccine with gel-primed and mineral oil-boosted regimen could produce improved immune response in broiler breeders[J]. Poultry Science, 2011a, 90(5): 1020~1022. 11 Lee D H, Park J K, Lee Y N, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals[J]. Vaccine, 2011b, 29(23): 4003~4007. 12 Liu L J, Suzuki T, Tsunemitsu H, et al. Efficient production of type 2 porcine circovirus-like particles by a recombinant baculovirus[J]. Archives of Virology, 2008, 153(12): 2291~2295. 13 Mena J A, Kamen A A. Insect cell technology is a versatile and robust vaccine manufacturing platform[J]. Expert Review of Vaccines, 2011, 10(7): 1063~1081. 14 Moormann R J, Bouma A, Kramps J A, et al. Development of a classical swine fever subunit marker vaccine and companion diagnostic test[J]. Veterinary Microbiology, 2000, 73(2~3): 209~219. 15 Pan Y S, Wei H J, Chang C C, et al. Construction and characterization of insect cell-derived influenza VLP: Cell binding, fusion, and EGFP incorporation[J]. Journal of Biomedicine & Biotechnology, 2010, 2010: 1~11. 16 Perez-Martin E, Gomez-Sebastian S, Argilaguet J M, et al. Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae[J]. Vaccine, 2010, 28(11): 2340~2349. 17 Rueda P, Fominaya J, Langeveld J P, et al. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles[J]. Vaccine, 2000, 19(7~8): 726~734. 18 Smith G E, Summers M D, Fraser M J. Production of human beta interferon in insect cells infected with a baculovirus expression vector[J]. Molecular and Cellular Biology, 1983, 3(12): 2156~2165. 19 Sokolenko S, George S, Wagner A, et al. Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks[J]. Biotechnology Advances, 2012, 30(3): 766~781. 20 Song J M, Hossain J, Yoo D G, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles[J]. Virology, 2010, 405(1): 165~175. 21 Song J M, Choi C W, Kwon S O, et al. Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity[J]. Journal of Proteome Research, 2011, 10(8): 3450~3459. 22 Stewart M, Bhatia Y, Athmaran T N, et al. Validation of a novel approach for the rapid production of immunogenic virus-like particles for bluetongue virus[J]. Vaccine, 2010, 28(17): 3047~3054. 23 Stewart M, Dubois E, Sailleau C, et al. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen[J]. Vaccine, 2013, 31(3): 553~558. 24 Tomiya N, Narang S, Lee Y C, et al. Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines[J]. Glycoconjugate Journal, 2004, 21(6): 343~360. 25 Tretyakova I, Pearce M B, Florese R, et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses[J]. Virology, 2013, 442(1): 67~73. 26 Vicente T, Roldao A, Peixoto C, et al. Large-scale production and purification of VLP-based vaccines[J]. Journal of Invertebrate Pathology, 2011, 107(Suppl): S42~S48. 27 Wang C C, Chen J R, Tseng Y C, et al. Glycans on influenza hemagglutinin affect receptor binding and immune response[J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(43): 18137~18142. 28 Wu P C, Lin W L, Wu C M, et al. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development[J]. Applied Microbiology and Biotechnology, 2012, 95(6): 1501~1507. |